CA2554996A1 - Tetrahydrobenzo[d]azepin-2- one derivatives and the use thereof for treating cardiovascular diseases - Google Patents

Tetrahydrobenzo[d]azepin-2- one derivatives and the use thereof for treating cardiovascular diseases Download PDF

Info

Publication number
CA2554996A1
CA2554996A1 CA002554996A CA2554996A CA2554996A1 CA 2554996 A1 CA2554996 A1 CA 2554996A1 CA 002554996 A CA002554996 A CA 002554996A CA 2554996 A CA2554996 A CA 2554996A CA 2554996 A1 CA2554996 A1 CA 2554996A1
Authority
CA
Canada
Prior art keywords
alkyl
formula
group
compound
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002554996A
Other languages
English (en)
French (fr)
Inventor
Nils Griebenow
Timo Flessner
Michael Haerter
Martin Raabe
Anja Buchmueller
Hilmar Bischoff
Peter Ellinghaus
Peter Kolkhof
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2554996A1 publication Critical patent/CA2554996A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002554996A 2004-02-10 2005-02-01 Tetrahydrobenzo[d]azepin-2- one derivatives and the use thereof for treating cardiovascular diseases Abandoned CA2554996A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004006325A DE102004006325A1 (de) 2004-02-10 2004-02-10 Tetrahydrobenzo[d]azepin-2-on-Derivate und ihre Verwendung
DE102004006325.7 2004-02-10
PCT/EP2005/000960 WO2005077907A1 (de) 2004-02-10 2005-02-01 Tetrahydrobenzo [d] azepin-2-on derivate und ihre verwendung zur behandlung von kardiovaskulären krankheiten

Publications (1)

Publication Number Publication Date
CA2554996A1 true CA2554996A1 (en) 2005-08-25

Family

ID=34801798

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002554996A Abandoned CA2554996A1 (en) 2004-02-10 2005-02-01 Tetrahydrobenzo[d]azepin-2- one derivatives and the use thereof for treating cardiovascular diseases

Country Status (7)

Country Link
US (1) US7662956B2 (https=)
EP (1) EP1716118B1 (https=)
JP (1) JP2007522159A (https=)
CA (1) CA2554996A1 (https=)
DE (2) DE102004006325A1 (https=)
ES (1) ES2304682T3 (https=)
WO (1) WO2005077907A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009509988A (ja) 2005-09-29 2009-03-12 サノフィ−アベンティス フェニル−及びピリジニル−1,2,4−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−2,4−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
MX2012001729A (es) 2009-08-26 2012-06-13 Sanofi Sa Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
KR102919209B1 (ko) 2018-08-10 2026-01-28 다이아핀 테라퓨틱스, 엘엘씨 트리-펩타이드 그리고 대사, 심장혈관 및 염증성 장애의 치료

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537987B1 (en) * 1996-06-20 2003-03-25 Pfizer Inc. 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors
HUP0301301A2 (hu) * 2000-06-23 2003-08-28 Takeda Chemical Industries Ltd. Benzoxazepinon-származékok és szkvalén szintáz inhibitorként való alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
FR2819512B1 (fr) * 2001-01-18 2003-02-21 Servier Lab Nouveaux composes cyclo[d] azepane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
WO2005077907A1 (de) 2005-08-25
EP1716118B1 (de) 2008-04-30
US7662956B2 (en) 2010-02-16
JP2007522159A (ja) 2007-08-09
ES2304682T3 (es) 2008-10-16
DE102004006325A1 (de) 2005-08-25
US20070287698A1 (en) 2007-12-13
DE502005003904D1 (de) 2008-06-12
EP1716118A1 (de) 2006-11-02

Similar Documents

Publication Publication Date Title
CA2554996A1 (en) Tetrahydrobenzo[d]azepin-2- one derivatives and the use thereof for treating cardiovascular diseases
KR102644889B1 (ko) Rock 억제제로서의 스피로헵타닐 히단토인
EP3164130B1 (en) Heteroaryl compounds useful as inhibitors of sumo activating enzyme
CN101820764B (zh) 治疗用异噁唑化合物
WO2012176763A1 (ja) 新規インダゾール誘導体
CN108137507A (zh) 基于mdm2的蛋白水解调节剂和相关的使用方法
JP2019537605A (ja) アルファvインテグリン阻害剤としてのシクロブタン−およびアゼチジン−含有の単環およびスピロ環式化合物
WO2005115975A1 (ja) アリールアルキルアミン化合物及びその製法
CN117143175A (zh) 靶向sos1蛋白泛素化调节的化合物及其制备方法和应用
NZ550006A (en) Aryl and heteroaryl-piperidinecarboxylate derivatives, the preparation and the use thereof in the form of FAAH enzyme inhibitors
KR20190076030A (ko) 알파 v 인테그린 억제제로서의 아졸 아미드 및 아민
EP2905279A1 (en) Imidazole derivative
JP6088491B2 (ja) 新規1位置換インダゾール誘導体
WO2012133509A1 (ja) 新規ベンズイミダゾール誘導体
US20100016299A1 (en) Substituted benzoxepino-isoxazoles and use thereof
CA2553202A1 (en) Tricyclic benzazepine derivatives as squalene synthase inhibitors used for the treatment of cardiovascular diseases
EP1915364A1 (en) Pyrazole derivatives as therapeutic agents
JP2014073982A (ja) 新規ベンズイミダゾール誘導体からなる医薬
TW201038562A (en) Azetidines as histamine H3 receptor antagonists
CA2475320A1 (en) Quinoxalinones and their use especially in the treatment of cardiovascular diseases
MXPA06007981A (en) Tricyclic benzazepine derivatives as squalene synthase inhibitors used for the treatment of cardiovascular diseases
NZ626745B2 (en) Cyclic amide derivatives as inhibitors of 11 - beta - hydroxysteroid dehydrogenase and uses thereof
HK1237266A1 (en) Heteroaryl compounds useful as inhibitors of sumo activating enzyme
HK1237266B (en) Heteroaryl compounds useful as inhibitors of sumo activating enzyme
CA2583302A1 (en) Novel oxadiazinone derivatives and use thereof as ppar-alpha modulators

Legal Events

Date Code Title Description
FZDE Discontinued